Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1

Cytokine and Growth Factor Reviews

Volumn 22, Issue 5-6, 2011, Pages 311-319

  Van Hauwermeiren, Filip ^a,b   Vandenbroucke, Roosmarijn E ^a,b   Libert, Claude ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Adverse effects; Autoimmunity; Therapy; TNF

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CYTOKINE; ETANERCEPT; GAMMA INTERFERON; GOLIMUMAB; IMMUNOGLOBULIN F(AB) FRAGMENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; CROHN DISEASE; CYTOKINE PRODUCTION; ENTERITIS; GENE DELETION; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; INFECTION RISK; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; UNSPECIFIED SIDE EFFECT;

ANIMALS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOMODULATION; IRRITABLE BOWEL SYNDROME; MULTIPLE SCLEROSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 82955236074     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2011.09.004     Document Type: Review

References (113)

1. Tracey K.J., Fong Y., Hesse D.G., Manogue K.R., Lee A.T., Kuo G.C., et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987, 330:662-664.
2. Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80kDa tumor necrosis factor receptor. Cell 1995, 83:793-802.
3. Kontoyiannis D., Pasparakis M., Pizarro T.T., Cominelli F., Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999, 10:387-398.
4. Gardam M.A., Keystone E.C., Menzies R., Manners S., Skamene E., Long R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. The Lancet Infectious Diseases 2003, 3:148-155.
5. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA: The Journal of the American Medical Association 2006, 295:2275-2285.
6. Ramos-Casals M., Brito-Zeron P., Munoz S., Soria N., Galiana D., Bertolaccini L., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007, 86:242-251.
7. Shakoor N., Michalska M., Harris C.A., Block J.A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002, 359:579-580.
8. Tack C.J., Kleijwegt F.S., Van Riel P.L., Roep B.O. Development of type 1 diabetes in a patient treated with anti-TNF-alpha therapy for active rheumatoid arthritis. Diabetologia 2009, 52:1442-1444.
9. Jarrett S.J., Cunnane G., Conaghan P.G., Bingham S.J., Buch M.H., Quinn M.A., et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. The Journal of Rheumatology 2003, 30:2287-2291.
10. Mohan N., Edwards E.T., Cupps T.R., Oliverio P.J., Sandberg G., Crayton H., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis and Rheumatism 2001, 44:2862-2869.
11. de Gannes G.C., Ghoreishi M., Pope J., Russell A., Bell D., Adams S., et al. Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Archives of Dermatology 2007, 143:223-231.
12. Calzascia T., Pellegrini M., Hall H., Sabbagh L., Ono N., Elford A.R., et al. TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. The Journal of Clinical Investigation 2007, 117:3833-3845.
13. Keystone E.C. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?.: a review of longterm data. The Journal of Rheumatology 2011, 38:1552-1562.
14. Diak P., Siegel J., La Grenade L., Choi L., Lemery S., McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis and Rheumatism 2010, 62:2517-2524.
15. Shibata H., Yoshioka Y., Abe Y., Ohkawa A., Nomura T., Minowa K., et al. The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF. Biomaterials 2009, 30:6638-6647.
16. Nomura T., Abe Y., Kamada H., Shibata H., Kayamuro H., Inoue M., et al. Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice. Journal of Controlled Release: Official Journal of the Controlled Release Society 2011, 149:8-14.
17. Arntz O.J., Geurts J., Veenbergen S., Bennink M.B., van den Brand B.T., Abdollahi-Roodsaz S., et al. A crucial role for tumor necrosis factor receptor 1 in synovial lining cells and the reticuloendothelial system in mediating experimental arthritis. Arthritis Research and Therapy 2010, 12:R61.
18. Kassiotis G., Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. The Journal of Experimental Medicine 2001, 193:427-434.
19. Zalevsky J., Secher T., Ezhevsky S.A., Janot L., Steed P.M., O'Brien C., et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. Journal of Immunology 2007, 179:1872-1883.
20. Alexopoulou L., Kranidioti K., Xanthoulea S., Denis M., Kotanidou A., Douni E., et al. Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. European Journal of Immunology 2006, 36:2768-2780.
21. Faustman D., Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nature Reviews Drug Discovery 2010, 9:482-493.
22. Clement S.L., Scheckel C., Stoecklin G., Lykke-Andersen J. Phosphorylation of tristetraprolin by MK2 impairs AU-rich element mRNA decay by preventing deadenylase recruitment. Molecular and Cellular Biology 2011, 31:256-266.
23. McDermott M.F., Aksentijevich I., Galon J., McDermott E.M., Ogunkolade B.W., Centola M., et al. Germline mutations in the extracellular domains of the 55kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999, 97:133-144.
24. Xanthoulea S., Pasparakis M., Kousteni S., Brakebusch C., Wallach D., Bauer J., et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. The Journal of Experimental Medicine 2004, 200:367-376.
25. Chan F.K., Chun H.J., Zheng L., Siegel R.M., Bui K.L., Lenardo M.J. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000, 288:2351-2354.
26. Micheau O., Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003, 114:181-190.
27. Fotin-Mleczek M., Henkler F., Samel D., Reichwein M., Hausser A., Parmryd I., et al. Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. Journal of Cell Science 2002, 115:2757-2770.
28. Baxter G.T., Kuo R.C., Jupp O.J., Vandenabeele P., MacEwan D.J. Tumor necrosis factor-alpha mediates both apoptotic cell death and cell proliferation in a human hematopoietic cell line dependent on mitotic activity and receptor subtype expression. The Journal of Biological Chemistry 1999, 274:9539-9547.
29. Eissner G., Kolch W., Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine and Growth Factor Reviews 2004, 15:353-366.
30. Horiuchi T., Mitoma H., Harashima S., Tsukamoto H., Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology 2010, 49:1215-1228.
31. Pasparakis M., Alexopoulou L., Episkopou V., Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. The Journal of Experimental Medicine 1996, 184:1397-1411.
32. Laichalk L.L., Kunkel S.L., Strieter R.M., Danforth J.M., Bailie M.B., Standiford T.J. Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia. Infection and Immunity 1996, 64:5211-5218.
33. Pavic I., Polic B., Crnkovic I., Lucin P., Jonjic S., Koszinowski U.H. Participation of endogenous tumour necrosis factor alpha in host resistance to cytomegalovirus infection. The Journal of General Virology 1993, 74(Pt 10):2215-2223.
34. Kneilling M., Mailhammer R., Hultner L., Schonberger T., Fuchs K., Schaller M., et al. Direct crosstalk between mast cell-TNF and TNFR1-expressing endothelia mediates local tissue inflammation. Blood 2009, 114:1696-1706.
35. Kim E.Y., Teh H.S. Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28. Journal of Immunology 2004, 173:4500-4509.
36. Aspalter R.M., Eibl M.M., Wolf H.M. Regulation of TCR-mediated T cell activation by TNF-RII. Journal of Leukocyte Biology 2003, 74:572-582.
37. Xu J., Chakrabarti A.K., Tan J.L., Ge L., Gambotto A., Vujanovic N.L. Essential role of the TNF-TNFR2 cognate interaction in mouse dendritic cell-natural killer cell crosstalk. Blood 2007, 109:3333-3341.
38. Chen X., Baumel M., Mannel D.N., Howard O.M., Oppenheim J.J. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+ CD25+ T regulatory cells. Journal of Immunology 2007, 179:154-161.
39. Birkland T.P., Sypek J.P., Wyler D.J. Soluble TNF and membrane TNF expressed on CD4+ T lymphocytes differ in their ability to activate macrophage antileishmanial defense. Journal of Leukocyte Biology 1992, 51:296-299.
40. Musicki K., Briscoe H., Tran S., Britton W.J., Saunders B.M. Differential requirements for soluble and transmembrane tumor necrosis factor in the immunological control of primary and secondary Listeria monocytogenes infection. Infection and Immunity 2006, 74:3180-3189.
41. Torres D., Janot L., Quesniaux V.F., Grivennikov S.I., Maillet I., Sedgwick J.D., et al. Membrane tumor necrosis factor confers partial protection to Listeria infection. The American Journal of Pathology 2005, 167:1677-1687.
42. Lees C.W., Ironside J., Wallace W.A., Satsangi J. Resolution of non-small-cell lung cancer after withdrawal of anti-TNF therapy. The New England Journal of Medicine 2008, 359:320-321.
43. Zhao X., Mohaupt M., Jiang J., Liu S., Li B., Qin Z. Tumor necrosis factor receptor 2-mediated tumor suppression is nitric oxide dependent and involves angiostasis. Cancer Research 2007, 67:4443-4450.
44. Clark J., Vagenas P., Panesar M., Cope A.P. What does tumour necrosis factor excess do to the immune system long term?. Annals of the Rheumatic Diseases 2005, 64(Suppl. 4):iv70-iv76.
45. Marino M.W., Dunn A., Grail D., Inglese M., Noguchi Y., Richards E., et al. Characterization of tumor necrosis factor-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:8093-8098.
46. Zganiacz A., Santosuosso M., Wang J., Yang T., Chen L., Anzulovic M., et al. TNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. The Journal of Clinical Investigation 2004, 113:401-413.
47. Aspalter R.M., Wolf H.M., Eibl M.M. Chronic TNF-alpha exposure impairs TCR-signaling via TNF-RII but not TNF-RI. Cellular Immunology 2005, 237:55-67.
48. Church L.D., Hessler G., Goodall J.E., Rider D.A., Workman C.J., Vignali D.A., et al. TNFR1-induced sphingomyelinase activation modulates TCR signaling by impairing store-operated Ca2+ influx. Journal of Leukocyte Biology 2005, 78:266-278.
49. Notley C.A., Inglis J.J., Alzabin S., McCann F.E., McNamee K.E., Williams R.O. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. The Journal of Experimental Medicine 2008, 205:2491-2497.
50. Elicabe R.J., Cargnelutti E., Serer M.I., Stege P.W., Valdez S.R., Toscano M.A., et al. Lack of TNFR p55 results in heightened expression of IFN-gamma and IL-17 during the development of reactive arthritis. Journal of Immunology 2010, 185:4485-4495.
51. Aerts N.E., De Knop K.J., Leysen J., Ebo D.G., Bridts C.H., Weyler J.J., et al. Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression. Rheumatology 2010, 49:2264-2272.
52. Raveney B.J., Copland D.A., Calder C.J., Dick A.D., Nicholson L.B. TNFR1 signalling is a critical checkpoint for developing macrophages that control of T-cell proliferation. Immunology 2010, 131:340-349.
53. Zakharova M., Ziegler H.K. Paradoxical anti-inflammatory actions of TNF-alpha: inhibition of IL-12 and IL-23 via TNF receptor 1 in macrophages and dendritic cells. Journal of Immunology 2005, 175:5024-5033.
54. Menges M., Rossner S., Voigtlander C., Schindler H., Kukutsch N.A., Bogdan C., et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. The Journal of Experimental Medicine 2002, 195:15-21.
55. Mizoguchi E., Hachiya Y., Kawada M., Nagatani K., Ogawa A., Sugimoto K., et al. TNF receptor type I-dependent activation of innate responses to reduce intestinal damage-associated mortality. Gastroenterology 2008, 134:470-480.
56. Williams-Skipp C., Raman T., Valuck R.J., Watkins H., Palmer B.E., Scheinman R.I. Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model. Arthritis and Rheumatism 2009, 60:408-418.
57. Raveney B.J., Copland D.A., Dick A.D., Nicholson L.B. TNFR1-dependent regulation of myeloid cell function in experimental autoimmune uveoretinitis. Journal of Immunology 2009, 183:2321-2329.
58. Wing K., Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nature Immunology 2010, 11:7-13.
59. Chen X., Oppenheim J.J. TNF-alpha: an activator of CD4+ FoxP3+ TNFR2+ regulatory T cells. Current Directions in Autoimmunity 2010, 11:119-134.
60. Chen X., Subleski J.J., Kopf H., Howard O.M., Mannel D.N., Oppenheim J.J. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+ CD25+ FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. Journal of Immunology 2008, 180:6467-6471.
61. Kim J.M., Rasmussen J.P., Rudensky A.Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nature Immunology 2007, 8:191-197.
62. Hamano R., Huang J., Yoshimura T., Oppenheim J.J., Chen X. TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. European Journal of Immunology 2011, 41:2010-2020.
63. Ma H.L., Napierata L., Stedman N., Benoit S., Collins M., Nickerson-Nutter C., et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis and Rheumatism 2010, 62:430-440.
64. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999, 53:457-465.
65. Liu J., Marino M.W., Wong G., Grail D., Dunn A., Bettadapura J., et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nature Medicine 1998, 4:78-83.
66. Ban L., Zhang J., Wang L., Kuhtreiber W., Burger D., Faustman D.L. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:13644-13649.
67. Twu Y.C., Gold M.R., Teh H.S. TNFR1 delivers pro-survival signals that are required for limiting TNFR2-dependent activation-induced cell death (AICD) in CD8+ T cells. European Journal of Immunology 2011, 41:335-344.
68. Grewal I.S., Grewal K.D., Wong F.S., Picarella D.E., Janeway C.A., Flavell R.A. Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. The Journal of Experimental Medicine 1996, 184:1963-1974.
69. Jacob C.O., McDevitt H.O. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 1988, 331:356-358.
70. Kaymakcalan Z., Sakorafas P., Bose S., Scesney S., Xiong L., Hanzatian D.K., et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clinical Immunology 2009, 131:308-316.
71. Nesbitt A., Fossati G., Bergin M., Stephens P., Stephens S., Foulkes R., et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflammatory Bowel Diseases 2007, 13:1323-1332.
72. Scallon B., Cai A., Solowski N., Rosenberg A., Song X.Y., Shealy D., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. The Journal of Pharmacology and Experimental Therapeutics 2002, 301:418-426.
73. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacology and Therapeutics 2008, 117:244-279.
74. Furst D.E., Wallis R., Broder M., Beenhouwer D.O. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Seminars in Arthritis and Rheumatism 2006, 36:159-167.
75. Steed P.M., Tansey M.G., Zalevsky J., Zhukovsky E.A., Desjarlais J.R., Szymkowski D.E., et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 2003, 301:1895-1898.
76. Zettlitz K.A., Lorenz V., Landauer K., Munkel S., Herrmann A., Scheurich P., et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs 2010, 2:639-647.
77. Huang X.W., Yang J., Dragovic A.F., Zhang H., Lawrence T.S., Zhang M. Antisense oligonucleotide inhibition of tumor necrosis factor receptor 1 protects the liver from radiation-induced apoptosis. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2006, 12:2849-2855.
78. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. The EMBO Journal 1991, 10:4025-4031.
79. Shealy D.J., Wooley P.H., Emmell E., Volk A., Rosenberg A., Treacy G., et al. Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Research 2002, 4:R7.
80. Taylor P.C., Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nature Reviews Rheumatology 2009, 5:578-582.
81. Campbell I.K., O'Donnell K., Lawlor K.E., Wicks I.P. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. The Journal of Clinical Investigation 2001, 107:1519-1527.
82. Piguet P.F., Grau G.E., Vesin C., Loetscher H., Gentz R., Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992, 77:510-514.
83. Williams R.O., Feldmann M., Maini R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:9784-9788.
84. Mori L., Iselin S., De Libero G., Lesslauer W. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. Journal of Immunology 1996, 157:3178-3182.
85. Lees C.W., Satsangi J. Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. Expert Review of Gastroenterology and Hepatology 2009, 3:513-534.
86. Cerf-Bensussan N., Gaboriau-Routhiau V. The immune system and the gut microbiota: friends or foes?. Nature Reviews Immunology 2010, 10:735-744.
87. Nenci A., Becker C., Wullaert A., Gareus R., van Loo G., Danese S., et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007, 446:557-561.
88. Roulis M., Armaka M., Manoloukos M., Apostolaki M., Kollias G. Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathology. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:5396-5401.
89. Armaka M., Apostolaki M., Jacques P., Kontoyiannis D.L., Elewaut D., Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. The Journal of Experimental Medicine 2008, 205:331-337.
90. Guma M., Stepniak D., Shaked H., Spehlmann M.E., Shenouda S., Cheroutre H., et al. Constitutive intestinal NF-κB does not trigger destructive inflammation unless accompanied by MAPK activation. The Journal of Experimental Medicine 2011.
91. Naito Y., Takagi T., Handa O., Ishikawa T., Nakagawa S., Yamaguchi T., et al. Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice. Journal of Gastroenterology and Hepatology 2003, 18:560-569.
92. Dayer Schneider J., Seibold I., Saxer-Sekulic N., Paredes B.E., Saurer L., Mueller C. Lack of TNFR2 expression by CD4(+) T cells exacerbates experimental colitis. European Journal of Immunology 2009, 39:1743-1753.
93. Holtmann M.H., Douni E., Schutz M., Zeller G., Mudter J., Lehr H.A., et al. Tumor necrosis factor-receptor 2 is up-regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo. European Journal of Immunology 2002, 32:3142-3151.
94. Arnett H.A., Mason J., Marino M., Suzuki K., Matsushima G.K., Ting J.P. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nature Neuroscience 2001, 4:1116-1122.
95. Chadwick W., Magnus T., Martin B., Keselman A., Mattson M.P., Maudsley S. Targeting TNF-alpha receptors for neurotherapeutics. Trends in Neurosciences 2008, 31:504-511.
96. Veroni C., Gabriele L., Canini I., Castiello L., Coccia E., Remoli M.E., et al. Activation of TNF receptor 2 in microglia promotes induction of anti-inflammatory pathways. Molecular and Cellular Neurosciences 2010, 45:234-244.
97. Shen Y., Li R., Shiosaki K. Inhibition of p75 tumor necrosis factor receptor by antisense oligonucleotides increases hypoxic injury and beta-amyloid toxicity in human neuronal cell line. The Journal of Biological Chemistry 1997, 272:3550-3553.
98. McAlpine F.E., Lee J.K., Harms A.S., Ruhn K.A., Blurton-Jones M., Hong J., et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiology of Disease 2009, 34:163-177.
99. He P., Zhong Z., Lindholm K., Berning L., Lee W., Lemere C., et al. Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. The Journal of Cell Biology 2007, 178:829-841.
100. McCoy M.K., Martinez T.N., Ruhn K.A., Szymkowski D.E., Smith C.G., Botterman B.R., et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2006, 26:9365-9375.
101. Fontaine V., Mohand-Said S., Hanoteau N., Fuchs C., Pfizenmaier K., Eisel U. Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2002, 22:RC216.
102. Monden Y., Kubota T., Inoue T., Tsutsumi T., Kawano S., Ide T., et al. Tumor necrosis factor-alpha is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction. American Journal of Physiology, Heart and Circulatory Physiology 2007, 293:H743-H753.
103. Goukassian D.A., Qin G., Dolan C., Murayama T., Silver M., Curry C., et al. Tumor necrosis factor-alpha receptor p75 is required in ischemia-induced neovascularization. Circulation 2007, 115:752-762.
104. Luo Y., Xu Z., Wan T., He Y., Jones D., Zhang H., et al. Endothelial-specific transgenesis of TNFR2 promotes adaptive arteriogenesis and angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 2010, 30:1307-1314.
105. Kagi D., Ho A., Odermatt B., Zakarian A., Ohashi P.S., Mak T.W. TNF receptor 1-dependent beta cell toxicity as an effector pathway in autoimmune diabetes. Journal of Immunology 1999, 162:4598-4605.
106. Deng G.M., Liu L., Kyttaris V.C., Tsokos G.C. Lupus serum IgG induces skin inflammation through the TNFR1 signaling pathway. Journal of Immunology 2010, 184:7154-7161.
107. Yamada Y., Webber E.M., Kirillova I., Peschon J.J., Fausto N. Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: requirement for type 1 but not type 2 receptor. Hepatology 1998, 28:959-970.
108. Shibata H., Yoshioka Y., Ohkawa A., Abe Y., Nomura T., Mukai Y., et al. The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis models. Cytokine 2008, 44:229-233.
109. Sudo K., Yamada Y., Moriwaki H., Saito K., Seishima M. Lack of tumor necrosis factor receptor type 1 inhibits liver fibrosis induced by carbon tetrachloride in mice. Cytokine 2005, 29:236-244.
110. Vielhauer V., Stavrakis G., Mayadas T.N. Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. The Journal of Clinical Investigation 2005, 115:1199-1209.
111. Ramesh G., Reeves W.B. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. American Journal of Physiology. Renal Physiology 2003, 285:F610-F618.
112. Nowak M., Gaines G.C., Rosenberg J., Minter R., Bahjat F.R., Rectenwald J., et al. LPS-induced liver injury in D-galactosamine-sensitized mice requires secreted TNF-alpha and the TNF-p55 receptor. American Journal of Physiology Regulatory, Integrative and Comparative Physiology 2000, 278:R1202-R1209.
113. Yin M., Wheeler M.D., Kono H., Bradford B.U., Gallucci R.M., Luster M.I., et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999, 117:942-952.